Mingjun Li on Muck Rack

Mingjun Li

As seen in: CNEWS (Convergence News Network), Arthritis & Rheumatology, Color Research & Application, Nature, Wiley Online Library, Frontiers, MDPI, JAMA: Journal of the American Medical Association, Royal Society of Chemistry, Canadian Journal of Infectious Diseases & Medical Microbiology, Dove Medical Press and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mingjun

Contact Mingjun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer : The HARMONi-A Randomized Clinical Trial

|
By HARMONi-A Study Investigators, Wenfeng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibin Song, Xiaobo Du, Yulan Sun, Wei Li, Longhua Sun, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Li Jia, Shen Xu, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Meiqi Shi, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Ying Liu, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Ruiqiang Ma, Hong Lu, Di Wu, Weineng Feng, Jianan Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Mengying Xia, Dongmei Lu, Mingxiu Hu, Zhongmin Wang, Baiyong Li, Michelle Xia, Li Zhang, Junguo Lu
| JAMA: Journal of the American Medical Association Verified
Key Points Question Does adding ivonescimab to chemotherapy improve overall survival in patients with epidermal growth factor receptor (EGFR) gene variant non–small cell lung cancer after disease progression with EGFR tyrosine kinase inhibitor (TKI) therapy? Findings In this phase 3, randomized, double-blind trial, ivonescimab plus chemotherapy significantly improved overall survival (median, 16.8 vs 14.1 months) and the 30-month survival rate (29.1% vs 18.4%) compared with chemotherapy alone.
Open in Who Shared Issue with article?

Hybrid Model for Offshore Wind Speed Prediction Based on SSA-EMF-SGMD Quadratic Decomposition

|
By Mingjun Li, Bingyan Li, Kequan Zhang
| ascelibrary.org
: Journal of Energy Engineering Volume 152, Issue 3 Get full access to this article View all available purchase options and get full access to this article. Data Availability Statement Some or all data, models, or code generated or used during the study are available from the corresponding author by request. Acknowledgments This research was supported by the Natural Science Foundation of Gansu Province (24JRRA408).
Open in Who Shared Issue with article?

Insight into the Role of Iron(III)-Reducing Microflora in the Arsenic Biogeochemistry of Earthworm (Pheretima guillemi) Guts

|
By Mingjun Li, Maria Ali, Haiming Wu, Yanmei Da
| dx.doi.org
Open in Who Shared Issue with article?
See all 33 licensed articles (38 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified